Capebel DT 1000mg Tablet

About

Capebel DT 1000mg Tablet contains Capecitabine, an oral fluoropyrimidine carbamate that acts as a prodrug of 5-fluorouracil (5-FU). It is selectively activated in tumor cells through a three-step enzymatic process, leading to the formation of 5-FU, which then interferes with DNA and RNA synthesis. This targeted mechanism results in the inhibition of cancer cell growth and induction of apoptosis, making it an effective agent in various oncology regimens. Its oral administration offers significant convenience for patients undergoing long-term treatment.

The drug's selective activation within malignant tissues helps to minimize systemic exposure to 5-FU, potentially reducing some of the severe side effects associated with intravenous 5-FU. It is widely used in both adjuvant and metastatic settings for several solid tumors, often as a cornerstone of combination chemotherapy protocols or as a monotherapy option.

Uses

• Treatment of metastatic colorectal cancer
• Adjuvant therapy for colon cancer
• Treatment of metastatic breast cancer
• Treatment of advanced gastric cancer

Directions For Use

Take Capebel DT 1000mg Tablet orally with water, typically within 30 minutes after a meal. Adhere strictly to the dosage and schedule prescribed by your healthcare provider.

Benefits

• Convenient oral administration
• Targeted action within tumor cells
• Effective against various solid tumors
• Can be used in combination therapies
• Potentially fewer hospital visits
• Improved quality of life for some patients

Side Effects

• Diarrhea
• Nausea and vomiting
• Hand-foot syndrome
• Fatigue and weakness
• Stomatitis (mouth sores)
• Abdominal pain
• Anorexia
• Constipation
• Hair thinning
• Skin rash
• Increased bilirubin

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may worsen gastrointestinal side effects and potentially interact with the medication.
• Pregnancy - Contraindicated in pregnancy due to significant risk of fetal harm. Use effective contraception during treatment and for a period after.
• Breastfeeding - Not recommended during breastfeeding as the drug may pass into breast milk and could harm the infant.
• Liver - Use with caution in patients with mild to moderate hepatic impairment; dose adjustments may be necessary. Avoid in severe impairment.
• Kidney - Dose reduction is required for patients with moderate to severe renal impairment. Close monitoring of kidney function is essential.
• Lung - Rare cases of interstitial lung disease have been reported; monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.